TD Asset Management Inc Sells 15,633 Shares of United Therapeutics Corporation $UTHR

Key Points

• TD Asset Management Inc has reduced its stake in United Therapeutics Corporation by 10.6%, selling 15,633 shares and holding 132,278 shares worth approximately $38 million at the end of the second quarter.
• Company insiders, including COO Michael Benkowitz and EVP Paul A. Mahon, have sold a significant number of shares recently, with over 292,000 shares sold last quarter, totaling nearly $119 million.
• Analysts have mixed views on United Therapeutics with target prices ranging from $330 to $580, and the company has an average rating of "Moderate Buy" based on analyst assessments.

TD Asset Management Inc reduced its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 10.6% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 132,278 shares of the biotechnology company's stock after selling 15,633 shares during the period. TD Asset Management Inc owned 0.29% of United Therapeutics worth $38,010,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of UTHR. Chung Wu Investment Group LLC bought a new stake in shares of United Therapeutics in the 2nd quarter valued at about $29,000. SVB Wealth LLC bought a new stake in shares of United Therapeutics in the 1st quarter valued at about $32,000. Geneos Wealth Management Inc. boosted its holdings in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after buying an additional 85 shares in the last quarter. Brooklyn Investment Group boosted its holdings in shares of United Therapeutics by 103.2% in the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after buying an additional 98 shares in the last quarter. Finally, WPG Advisers LLC bought a new stake in shares of United Therapeutics in the 1st quarter valued at about $60,000. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 22,500 shares of the company's stock in a transaction on Monday, October 13th. The shares were sold at an average price of $440.35, for a total transaction of $9,907,875.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $436.60, for a total transaction of $4,802,600.00. Following the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at $16,058,584.60. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 292,435 shares of company stock valued at $118,956,307. 10.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently commented on UTHR shares. JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. HC Wainwright lifted their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research note on Friday, September 5th. UBS Group lifted their target price on shares of United Therapeutics from $560.00 to $580.00 and gave the stock a "buy" rating in a research note on Monday, September 29th. Oppenheimer lifted their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research note on Friday, September 5th. Finally, Royal Bank Of Canada started coverage on shares of United Therapeutics in a research note on Friday, September 26th. They issued an "outperform" rating and a $569.00 target price for the company. Ten analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $457.21.

United Therapeutics Price Performance

UTHR opened at $432.69 on Friday. The firm has a fifty day moving average price of $383.05 and a 200 day moving average price of $327.06. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $459.48. The stock has a market cap of $19.52 billion, a P/E ratio of 16.89, a P/E/G ratio of 4.71 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same quarter in the prior year, the firm earned $5.85 earnings per share. The business's revenue for the quarter was up 11.7% on a year-over-year basis. Equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.